Antibodies
FG-4592
- 貨號 Cat. No.
- S1007
- 規格 Size
- 5~200mg
- 品牌 Brand
- Selleckchem
Description
FG-4592
Catalog No.S1007
FG-4592 is an HIF α prolyl hydroxylase inhibitor, stabilizes HIF-2 and induces EPO production. Phase 2/3.
| Size | Price | Stock | Quantity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
| Description | FG-4592 is an HIF α prolyl hydroxylase inhibitor, stabilizes HIF-2 and induces EPO production. Phase 2/3. | |||||
|---|---|---|---|---|---|---|
| Targets | HIF α prolyl hydroxylase | |||||
| IC50 | ||||||
| In vitro | FG-4592 is an oral inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase currently in clinical development for the treatment of anemia. FG-4592 stabilizes the activities of HIF, a cytosolic transcription factor, leading to activation of the genes associated with erythropoiesis, including erythropoietin and enzymes involved in iron metabolism. [1] | |||||
| In vivo | ||||||
| Features | ||||||
Protocol(Only for Reference)
References
Clinical Trial Information( data from http://clinicaltrials.gov)
| NCT Number | Recruitment | Conditions | Sponsor /Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01414075 | Active, not recruiting | Dialysis|Anemia | FibroGen | 2011-07 | Phase 2 |
| NCT01596855 | Completed | Anemia in End Stage Renal Disease | FibroGen|Ruijin Hospital|RenJi Hospital|Chang Zheng Hospital|Shanghai Xinhua Hospital|Peking University First Hospital|First Affiliated Hospital, Sun Yat-Sen University|Zhejiang University No 1. Hospital|Peking Union Medical College Hospital|Shenzhen People’s?Hospital | 2011-09 | Phase 2 |
| NCT01599507 | Completed | Anemia in Chronic Kidney Disease | FibroGen | 2011-12 | Phase 2 |
| NCT01630889 | Enrolling by invitation | Chronic Kidney Disease|End Stage Renal Disease|Anemia | FibroGen | 2012-05 | Phase 2|Phase 3 |
| NCT01750190 | Recruiting | Anemia | FibroGen|Astellas Pharma Europe B.V. | 2012-11 | Phase 3 |
Chemical Information
| Molecular Weight (MW) | 352.34 |
|---|---|
| Formula | C19H16N2O5 |
| CAS No. | 808118-40-3 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | N/A |
| Solubility (25°C) * | In vitro | DMSO | 71 mg/mL (201 mM) |
|---|---|---|---|
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| In vivo | 30% PEG400/0.5% Tween80/5% propylene glycol, | 30 mg/mL | |
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name | 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid |
|---|
Preparing Stock Solutions
| Stock Solution (1ml DMSO) | 1mM | 10mM | 20mM | 30mM |
|---|---|---|---|---|
| Mass(mg) | 0.35234 | 3.5234 | 7.0468 | 10.5702 |
